Topical steroid hazards

01Purpose and principlesWhat the treatment does and how it fits into care.

The benefit of an ocular corticosteroid depends on identifying a steroid-responsive inflammatory process and controlling any relevant infectious component. Topical delivery does not make the treatment harmless or confine all effects to visible surface redness. Steroids suppress inflammation and can make an eye appear more comfortable while an infection persists, corneal tissue weakens or intraocular pressure rises. Before prescribing or renewing treatment, establish who made the diagnosis, what examination was performed, the intended duration and who will review the response.

The main diagnostic hazard is treating an undifferentiated red eye. Epithelial herpes simplex, fungal disease and other microbial keratitis may deteriorate with inappropriate corticosteroid exposure. A combined antibiotic preparation does not cover every organism and cannot compensate for an unrecognised ulcer. The relationship between infection and steroids is nevertheless disease-specific: selected stromal herpetic inflammation may receive a specialist steroid regimen with antiviral treatment. That carefully assessed indication must not be generalised to an epithelial dendrite or a painful red eye without examination.

A safe prescription is a complete plan rather than a bottle name. Identify the affected eye, formulation and concentration, initial frequency, intended treatment period and how any taper will be decided. Explain why follow-up continues after pain improves. Review requires examination of inflammatory activity, corneal integrity, visual function and intraocular pressure as appropriate. The product information gives supervision thresholds, but these are not guaranteed safe intervals without monitoring: severe inflammation, glaucoma, a previous steroid response or vulnerable ocular tissue may require earlier and more frequent review.

Key points

Ocular corticosteroids can be valuable for established inflammatory disease, but redness alone is not an adequate prescribing indication.
Steroids can worsen or mask infection, including epithelial herpes simplex and fungal or amoebic corneal disease.
Pressure elevation may be asymptomatic; symptom improvement does not remove the need for ophthalmic monitoring.
Prolonged or intensive exposure can contribute to glaucoma, cataract, delayed healing and systemic steroid effects.
An antibiotic and steroid combination does not make empirical treatment of an unexamined red eye safe.
Write the treated eye, drug, strength, frequency, intended duration or taper, review date and urgent contact instructions explicitly.

02Indications, selection and cautionsWho may benefit, who needs urgent treatment and important alternatives.

Possible steroid-worsened infection

New or increasing pain, photophobia, discharge, a corneal opacity or persistent visual loss during treatment should trigger urgent reconsideration of infection and the original diagnosis.

Pressure response

Raised intraocular pressure can occur without a noticeable symptom, so the absence of headache or blurred vision cannot replace planned pressure measurements.

Tissue vulnerability

Corneal or scleral thinning and an unhealed epithelial defect increase concern for impaired healing or perforation and require specialist assessment of treatment suitability.

An incomplete prescription plan

Unclear indication, indefinite repeats, conflicting taper instructions or no named reviewing service creates avoidable risk even when the original steroid choice was appropriate.

Red flags requiring action

An undiagnosed red eye, corneal epithelial lesion or suspected microbial infection requires examination before steroid treatment is considered.
New pain, visual deterioration or a corneal white spot during treatment warrants urgent ophthalmic reassessment.
Known corneal or scleral thinning, previous steroid pressure response or glaucoma increases the need for a carefully supervised plan.

03Assessment before treatmentTests and checks that guide safe selection.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Baseline diagnosis and ocular examinationFirst step
Why
Confirm the indication and identify relevant infection or tissue damage.
Interpretation and limitations
Review slit-lamp findings, corneal integrity and the clinical context before initiating or renewing treatment; external redness alone is insufficient evidence.
02
Intraocular pressure measurement
Why
Detect baseline pressure risk and a subsequent steroid response.
Interpretation and limitations
Arrange assessment at intervals matched to product, intensity, duration and individual risk; normal symptoms do not establish that pressure remains safe.
03
Visual acuity and lens assessment
Why
Monitor visual function and investigate persistent or progressive blur.
Interpretation and limitations
Visual change may reflect the underlying disease, corneal complications, pressure damage or cataract and needs examination rather than automatic dose escalation.
04
Targeted microbiology or specialist imaging
Why
Investigate unexpected deterioration or a suspected alternative diagnosis.
Interpretation and limitations
Sampling and imaging are chosen according to corneal, intraocular or other findings; a routine topical antibiotic trial must not delay assessment of a threatened eye.

04Treatment approachPreparation, options, escalation and aftercare.

01Before prescribingEstablish the indication and supervisionFirst stepA clinician is considering ocular steroid initiation, renewal or a change in frequency.

1Confirm the examined diagnosis, corneal status, infection assessment and relevant history such as glaucoma or a previous steroid response.
2Select the appropriate preparation and record eye, concentration, dose, duration, intended taper and the service responsible for review.
3Explain administration and urgent warning symptoms, and ensure the patient can access the planned examination and pressure monitoring.

02During treatmentReview activity and adverse effects togetherThe patient is using a prescribed steroid for confirmed ocular inflammation.

1Check adherence and technique alongside inflammatory findings, vision, corneal integrity and pressure rather than judging success from comfort alone.
2Adjust frequency or taper according to the ophthalmic assessment and communicate any change in a single clear written schedule.
3Reassess the need for continued treatment before repeat prescribing, including whether treatment burden or adverse effects require a different specialist strategy.

03Deterioration or uncertaintyObtain urgent reassessment and a specific drop planPain, visual decline, a corneal lesion or uncertainty about the original diagnosis emerges during treatment.

1Contact ophthalmology urgently and provide the exact drug, dose, start date, current symptoms and any infection or procedure history.
2Do not independently intensify steroids or assume an added antibiotic resolves the diagnostic concern.
3Obtain clear instructions for ongoing doses and examination timing; prolonged prescribed therapy requires a clinician-directed adjustment rather than an improvised taper.

05Regimens, contraindications and interactionsTreatment details and the circumstances that modify them.

Provides a potent topical corticosteroid option for selected anterior ocular inflammation.

Prednisolone acetate 1% suspension, Pred Forte

For a confirmed steroid-responsive indication, the adult SmPC dose is one to two drops two to four times daily; the initial 24 to 48 hours may use two drops hourly. The ophthalmologist determines the indication-specific duration and taper.

Shake before use. Contraindications include untreated purulent infection, epithelial herpes simplex, fungal and mycobacterial ocular disease. Use beyond ten days requires strict ophthalmic supervision and pressure checks; thinning tissue, glaucoma, cataract and masked infection are important risks.

Provides an alternative topical corticosteroid when its preparation and potency suit the diagnosed inflammatory condition.

Dexamethasone 0.1% suspension, Maxidex

For severe inflammation under ophthalmic supervision, the SmPC permits one to two drops every 30 to 60 minutes until a satisfactory response occurs, then reduction towards one drop every four hours. Subsequent duration and taper follow the specialist examination.

Shake the suspension and use punctal occlusion. The SmPC contraindicates herpes simplex keratitis, specified viral ocular disease, fungal or untreated parasitic infection, mycobacterial infection and acute untreated bacterial infection. Use beyond one week requires ophthalmic supervision with regular pressure assessment.

06Complications, monitoring and follow-upAdverse effects, response and longer-term review.

Give the patient a written schedule and ask them to explain it back, particularly when the initial frequency is high or a taper changes across days.
Use the product-specific supervision requirements: Pred Forte beyond ten days and Maxidex beyond one week require ophthalmic oversight, with earlier monitoring when risk or severity warrants it.
Check for pressure elevation and continuing inflammation even when the eye feels comfortable; neither can be reliably excluded by symptom reporting alone.
Review bottle hygiene, opening expiry and administration; shake suspensions, avoid touching the tip and use punctal occlusion for about one minute to reduce drainage.
Leave at least five minutes between different eye drops when used together, follow product instructions and clarify the order when an ointment is also prescribed.
Ensure renewed pain, photophobia, a corneal opacity or worsening vision leads to urgent contact before the scheduled appointment.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Different products have different instructions

Steroid potency, formulation and licensed schedules differ. Substituting a preparation or copying another product's frequency without an appropriate prescription can alter treatment intensity and risk.

An antibiotic combination has limits

The antibacterial component does not reliably treat viral, fungal or amoebic infection. A combination bottle therefore does not remove the need to establish the cause of redness.

Systemic absorption still occurs

Ocular drugs can drain through the nasolacrimal system and be absorbed. Punctal occlusion reduces drainage, and prolonged intensive treatment warrants particular care in susceptible patients and children.

Tapering requires a clinical reason

Reducing treatment follows control of the underlying inflammation and the prescriber's plan. A fixed generic taper cannot account for different diagnoses, relapse risks or new infectious concerns.

Contact lenses require specific advice

Active ocular infection or significant inflammation usually prevents lens wear. Do not interpret a preservative-related removal interval as permission to resume lenses during an unresolved eye disorder.

Interactions can increase systemic exposure

Ask about ritonavir, cobicistat and other strong CYP3A inhibitors. These can increase systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, despite ocular administration. Coordinate the interaction assessment, monitoring and any treatment change with the ophthalmic and prescribing teams, particularly after intensive or prolonged use.

08Common pitfallsFrequent interpretation and management errors.

01
Renewing steroid drops indefinitely because they previously relieved redness, without confirming the indication and monitoring arrangements.
02
Assuming pressure is normal because the patient has no headache and reports improved comfort.
03
Adding a steroid-containing preparation to a suspected microbial ulcer before corneal assessment.
04
Treating the product's supervision threshold as a guarantee that every shorter course needs no review.
05
Allowing patients to alternate between old and new taper instructions or restart an expired bottle for a later unexamined red eye.